Welcome to our dedicated page for Structure Therapeutics ADR SEC filings (Ticker: GPCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Structure Therapeutics Inc. (NASDAQ: GPCR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Structure Therapeutics is incorporated in the Cayman Islands and its American Depositary Shares, each representing three ordinary shares, are registered and listed on the Nasdaq Global Market under the symbol GPCR. The company files reports and current updates with the U.S. Securities and Exchange Commission in connection with its operations and capital markets activities.
Investors reviewing GPCR SEC filings will find current reports on Form 8-K that cover topics such as quarterly financial results, corporate updates, and outcomes of the annual general meeting of shareholders. For example, the company has furnished press releases announcing second and third quarter financial results and business updates via Form 8-K, and has reported shareholder voting results on director elections, auditor ratification, and advisory votes on executive compensation and say-on-frequency matters.
Structure Therapeutics also utilizes an automatic shelf registration statement on Form S-3 to conduct public offerings of American Depositary Shares and pre-funded warrants. Related prospectus supplements and offering documents are filed with the SEC and referenced in the company’s press releases. These filings provide details on the terms of upsized underwritten public offerings, gross proceeds, and the involvement of joint book-running managers and co-managers.
Through this filings page, users can monitor how Structure Therapeutics reports its financial condition, shareholder actions, and significant corporate events in its SEC submissions. Stock Titan enhances access to these documents with tools to quickly locate relevant 8-Ks and registration-related materials and to follow the company’s ongoing reporting history as a Nasdaq-listed clinical-stage biopharmaceutical company focused on oral small molecule GPCR-targeted therapies.
Structure Therapeutics Inc. has called its 2026 annual general meeting for June 17, 2026 at 9:00 a.m. Pacific Time, to be held virtually via live audio webcast. Shareholders of record at 5:00 p.m. Eastern Time on April 20, 2026 may attend online and vote.
Investors will vote on three items: electing three Class III directors to terms ending at the 2029 meeting, ratifying Ernst & Young LLP as independent auditor for the year ending December 31, 2026, and approving on an advisory basis the compensation of named executive officers.
The company reports 213,213,565 ordinary shares outstanding as of the record date, with a one‑third quorum requirement. The board is classified into three staggered classes and a majority of directors are independent, with separate chair and CEO roles and active audit, compensation, nominating, and R&D committees overseeing risk, strategy, and governance.
Structure Therapeutics Inc. reported that its COO & GC, Matthew Lang, received new equity compensation awards. He was granted 184,614 restricted stock units, each representing one Ordinary Share, which vest in four equal annual installments starting on April 15, 2026, subject to his continued service. He also received a stock option for 223,776 Ordinary Shares at an exercise price of 18.08 per share, expiring on April 14, 2036. One-quarter of the option vests on the first anniversary of April 15, 2026, with the remainder vesting in 36 equal monthly installments, conditioned on continued service. The filing notes that each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. executive Matthew Lang, who serves as COO & GC, has filed an initial Form 3 as a reporting person. The filing shows no reported purchases, sales, gifts, tax withholdings, restructurings, or derivative exercises, and includes no derivative holdings in the excerpt provided.
FMR LLC, a ten percent owner of Structure Therapeutics Inc., reported open-market sales of American Depositary Shares (ADSs) of GPCR. Funds associated with FMR LLC sold 1,367 ADSs and 16,085 ADSs on April 14, 2026 at a weighted average price of $55.07 per ADS in separate transactions.
Each ADS represents three ordinary shares of Structure Therapeutics. After these sales, F-Prime Capital Partners Life Sciences Advisors Fund VI LP held 2,736 ADSs, and F-Prime Capital Partners Life Sciences Fund VI LP held 32,171 ADSs. A larger indirect position remains through ADSs representing 4,546,674 underlying ordinary shares.
Structure Therapeutics Inc. appointed Matthew Lang as Chief Operating Officer and General Counsel, effective April 15, 2026. He brings more than 15 years of executive experience at biopharmaceutical companies including Metsera, Lyell Immunopharma, Myovant Sciences and Gilead Sciences, as well as prior law firm experience.
Under his employment agreement, Mr. Lang will receive a base salary of $560,000 per year and an annual discretionary bonus targeted at 40% of salary, with no pro‑ration for 2026. He will be granted an option to purchase 223,776 ordinary shares, time-based RSUs for 184,614 ordinary shares and performance-based RSUs for 46,155 ordinary shares, all subject to multi-year vesting tied to service and specified performance milestones through 2029.
Structure Therapeutics Inc. Chief Development Officer Ashley Hall reported compensation-related equity grants. Hall received an option to buy 59,073 ordinary shares at an exercise price of $16.82 per share, expiring on March 18, 2036, and now holds 59,073 derivative shares from this grant.
Hall was also awarded 47,706 restricted stock units, each representing one ordinary share, bringing direct ordinary share holdings to 155,187 shares after the award. The RSUs vest 1/4 each year on the anniversaries of March 1, 2026, while the option vests 1/4 on March 1, 2027 and monthly thereafter, subject to continued service.
Structure Therapeutics Inc. reported that Chief Medical Officer Blas Coll Crespo received equity compensation on March 19, 2026. He was granted an employee stock option for 93,984 Ordinary Shares at an exercise price of $16.82 per share, expiring in 2036.
He also received 75,897 Restricted Stock Units, each representing one Ordinary Share, vesting in four equal annual installments starting March 1, 2026, subject to continued service. Following these grants, he directly owns 280,878 Ordinary Shares. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. chief technology officer Yingli Ma reported equity compensation grants rather than market trades. Ma received an option to buy 40,278 Ordinary Shares at an exercise price of $16.82 per share, expiring in 2036, and 32,526 restricted stock units representing Ordinary Shares. The RSUs vest in four annual installments starting March 1, 2026, while the option vests 25% on March 1, 2027, with the remainder vesting monthly over three years. After the RSU grant, Ma directly holds 139,917 Ordinary Shares. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. reported that Chief Scientific Officer Xichen Lin received new equity awards. Lin was granted an employee stock option for 53,703 ordinary shares at an exercise price of $16.82 per share, expiring on March 18, 2036. One quarter of these option shares will vest on March 1, 2027, with the remainder vesting in 36 equal monthly installments, subject to continued service.
Lin was also awarded 43,368 restricted stock units, each representing one ordinary share. These RSUs vest one quarter annually on each anniversary of March 1, 2026, subject to continued service. Following the RSU grant, Lin directly holds 228,960 ordinary shares. The company notes that each American Depositary Share represents three ordinary shares.